Xia Jufeng, Inagaki Yoshinori, Gao Jianjun, Qi Fanghua, Song Peipei, Han Guohua, Sawakami Tatsuo, Gao Bo, Luo Chuan, Kokudo Norihiro, Hasegawa Kiyoshi, Sakamoto Yoshihiro, Tang Wei
* Hepato-Biliary-Pancreatic Surgery Division, Department of Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
† Department of Pharmacology, School of Pharmaceutical Sciences, Qingdao University, Qingdao, Shandong, China.
Am J Chin Med. 2017;45(7):1537-1556. doi: 10.1142/S0192415X17500835. Epub 2017 Sep 25.
Cinobufacini, a traditional Chinese medicine, has been used widely for cancer treatment, such as hepatocellular carcinoma (HCC), sarcoma, and leukemia. Previous studies done by our lab indicated that cinobufacini could suppress HCC cells through mitochondria-mediated and Fas-mediated apoptotic pathways. Here, we use a combination of cinobufacini and doxorubicin to inhibit the growth of HCC cells. The combination group induced more significant apoptosis by affecting proteins and RNA of apoptosis-related elements, such as Bcl-2, Bax, Bid, and cytochrome c. Furthermore, cinobufacini, as a mixture of a number of components, had stronger apoptosis-inducing activity than particular individual components or a simple mixture of a few components. Overall, these results suggested that the combination of cinobufacini and doxorubicin may provide a new strategy for inhibiting the proliferation of HCC cells.
华蟾素是一种传统中药，已被广泛用于癌症治疗，如肝细胞癌（HCC）、肉瘤和白血病。我们实验室之前的研究表明，华蟾素可通过线粒体介导和Fas介导的凋亡途径抑制肝癌细胞。在这里，我们使用华蟾素和阿霉素的组合来抑制肝癌细胞的生长。联合组通过影响凋亡相关元件的蛋白质和RNA，如Bcl-2、Bax、Bid和细胞色素c，诱导了更显著的凋亡。此外，华蟾素作为多种成分的混合物，比特定的单个成分或几种成分的简单混合物具有更强的凋亡诱导活性。总体而言，这些结果表明，华蟾素和阿霉素的组合可能为抑制肝癌细胞增殖提供一种新策略。
